Drug Trial Radar · NCT07673458
An Early-stage Clinical Trial to Evaluate the Safety, Absorption, and Disposition of YR001 Ointment Following Topical Application on the Skin of Healthy Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Jun 22, 2026
Primary completion
Sep 18, 2026
Study completion Nov 11, 2026
Sponsor
- Lead sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, local tolerability, and pharmacokinetic (PK) profile of YR001 Topical Ointment in healthy Chinese participants. This is a first-in-China, Phase I study designed to assess the drug's systemic absorption and disposition following single and multiple topical applications. The main questions it aims to answer are: What is the safety and local tolerability profile of YR001 Topical Ointment after single-dose and multiple-dose administration in healthy Chinese participants? What are the pharmacokinetic characteristics (e.g., plasma drug concentrations) of YR001 Topical Ointment after single and multiple topical applications? Researchers will compare participants receiving YR001 Topical Ointment with participants receiving vehicle (placebo) to determine whether the safety profile and local tolerability of YR001 are comparable to placebo. Participants will: Receive topical application of either YR001 Topical Ointment or matching placebo (vehicle) on approximately 10% or 20% of their body surface area, depending on the assigned group Undergo serial blood sampling for pharmacokinetic assessments at specified time points before and after drug administration Complete safety evaluations including physical examinations, vital signs, laboratory tests (hematology, biochemistry, coagulation, thyroid function, urinalysis), 12-lead ECGs, and local tolerability assessments at the application site Remain in the clinical unit for specified periods during the dosing and follow-up phases, with total study participation duration up to approximately 30 days per participant
Conditions
- Health Adult Subjects
Interventions
PA032Drug
YR001 ointment containing 2% PA032 (Kv1.3 potassium channel blocker) for topical application
Vehicle OintmentDrug
Matching vehicle ointment without active ingredient (identical appearance, packaging, and administration)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of YR001 Ointment: Incidence of Adverse EventsTime frame: From signing of informed consent through 7 days after the last dose (up to approximately 30 days for Group 1; up to 21 days for Groups 2-4)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hebei CNPC Central Hospital
Langfang, Hebei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.